An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma
Open Access
- 1 June 2023
- journal article
- research article
- Published by Springer Nature in BMC Bioinformatics
- Vol. 24 (1) , 1-22
Abstract
Background: N6-methyladenosine (m6A) modification is involved in tumorigenesis and progression as well as closely correlated with stem cell differentiation and pluripotency. Moreover, tumor progression includes the acquisition of stemness characteristics and accumulating loss of differentiation phenotype. Therefore, we integrated m6A modification and stemness indicator mRNAsi to classify patients and predict prognosis for LGG. Methods: We performed consensus clustering, weighted gene co-expression network analysis, and least absolute shrinkage and selection operator Cox regression analysis to identify an m6A regulation- and mRNAsi-related prognostic index (MRMRPI). Based on this prognostic index, we also explored the differences in immune microenvironments between high- and low-risk populations. Next, immunotherapy responses were also predicted. Moreover, single-cell RNA sequencing data was further used to verify the expression of these genes in MRMRPI. At last, the tumor-promoting and tumor-associated macrophage polarization roles of TIMP1 in LGG were validated by in vitro experiments. Results: Ten genes (DGCR10, CYP2E1, CSMD3, HOXB3, CABP4, AVIL, PTCRA, TIMP1, CLEC18A, and SAMD9) were identified to construct the MRMRPI, which was able to successfully classify patients into high- and low-risk group. Significant differences in prognosis, immune microenvironment, and immunotherapy responses were found between distinct groups. A nomogram integrating the MRMRPI and other prognostic factors were also developed to accurately predict prognosis. Moreover, in vitro experiments illustrated that inhibition of TIMP1 could inhibit the proliferation, migration, and invasion of LGG cells and also inhibit the polarization of tumor-associated macrophages. Conclusion: These findings provide novel insights into understanding the interactions of m6A methylation regulation and tumor stemness on LGG development and contribute to guiding more precise immunotherapy strategies.Keywords
This publication has 58 references indexed in Scilit:
- Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expressionGenome Biology, 2016
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyAnnals of Oncology, 2016
- Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinomaArchives of Toxicology, 2016
- Retracted: CYP2E1 Rsa Ι/Pst Ι polymorphism and lung cancer susceptibility: a meta‐analysis involving 10,947 subjectsJournal of Cellular and Molecular Medicine, 2015
- T cell exclusion, immune privilege, and the tumor microenvironmentScience, 2015
- pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression LevelsPLOS ONE, 2014
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factorNeuro-Oncology, 2010
- Differential expression and localization of TIMP-1 and TIMP-4 in human gliomasBritish Journal of Cancer, 2001
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000